Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.

© www.doctor-4-u.co.uk/ via Flickr

The ATOMIC2 trial, which is being led from Oxford, will enrol 800 people who are being assessed at hospital with COVID-19 but felt well enough to be cared for at home. Half will receive Azithromycin for two weeks, while the rest will get regular care. Participants will also give samples of blood and samples from the nose so researchers can better understand the biology of the virus.

The first participant in the trial was recruited at Oxford’s John Radcliffe Hospital on Wednesday (3 June).

The trial, which has received funding from the NIHR Oxford Biomedical Research Centre (BRC), as well as the University of Oxford and Pfizer, will take place across 15 sites across England, Wales and Scotland. It complements two other national trials – RECOVERY and PRINCIPLE – which are testing Azithromycin in different categories of patients.

The trial’s Chief Investigator is Dr Tim Hinks of the University of Oxford’s Nuffield Department of Medicine and an Oxford BRC Senior Fellow. He said: “Azithromycin is an antibiotic with unusual anti-inflammatory and anti-viral properties, so it is being seen as a promising potential treatment for COVID-19.

Read the full story on the NIHR Oxford BRC website

Similar stories

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.